Literature DB >> 11246868

Effects of kidney-pancreas transplantation on atherosclerotic risk factors and endothelial function in patients with uremia and type 1 diabetes.

P Fiorina1, E La Rocca, M Venturini, F Minicucci, I Fermo, R Paroni, A D'Angelo, M Sblendido, V Di Carlo, M Cristallo, A Del Maschio, G Pozza, A Secchi.   

Abstract

Cardiovascular disease and the development of coronary artery disease play a pivotal role in increasing mortality in patients with type 1 diabetes. The aim of our study was to evaluate the effects of pancreas transplantation on atherosclerotic risk factors, endothelial-dependent dilation (EDD), and progression of intima media thickness (IMT) in patients with uremia and type 1 diabetes after kidney-alone (KA) or kidney-pancreas (KP) transplantation. A cross-sectional study comparing two groups of patients with type 1 diabetes was performed. Sixty patients underwent KP transplantation and 30 patients underwent KA transplantation. Age and cardiovascular risk profile were comparable in patients before transplantation. In all patients, atherosclerotic risks factors (lipid profile, fasting and post-methionine load plasma homocysteine, von Willebrand factor levels, D-dimer fragments, and fibrinogen) were assessed and Doppler echographic evaluation of IMT and endothelial function with flow-mediated and nitrate dilation of the brachial artery was performed. Twenty healthy subjects were chosen as controls (C) for EDD. Compared with patients undergoing KA transplantation, patients undergoing KP transplantation showed lower values for HbA1c (KP = 6.2 +/- 0.1% vs. KA = 8.4 +/- 0.5%; P < 0.01), fasting homocysteine (KP = 14.0 +/- 0.7 mcromol/l vs. KA = 19.0 +/- 2.0 micromol/l; P = 0.02), von Willebrand factor levels (KP = 157.9 +/- 8.6% vs. KA = 212.5 +/- 16.2%; P < 0.01), D-dimer fragments (KP = 0.29 +/- 0.02 microg/ml vs. KA = 0.73 +/- 0.11 microg/ml;P < 0.01), fibrinogen (KP = 363.0 +/- 11.1 mg/dl vs. KA = 397.6 +/- 19.4 mg/dl; NS), triglycerides (KP = 122.7 +/- 8.6 mg/dl vs. KA = 187.0 +/- 30.1 mg/dl; P = 0.01), and urinary albumin excretion rate (KP = 13.5 +/- 1.9 mg/24 h vs. KA = 57.3 +/- 26.3 mg/24 h; P < 0.01). Patients undergoing KP transplantation showed a normal EDD (KP = 6.21 +/- 2.42%, KA = 0.65 +/- 2.74%, C = 8.1 +/- 2.1%; P < 0.01), whereas no differences were observed in nitrate-dependent dilation. Moreover, IMT was lower in patients undergoing KP transplantation than in patients undergoing KA transplantation (KP = 0.74 +/- 0.03 mm vs. KA = 0.86 +/- 0.09 mm; P = 0.04). Our study showed that patients with type 1 diabetes have a lower atherosclerotic risk profile after KP transplantation than after KA transplantation. These differences are tightly correlated with metabolic control, fasting homocysteine levels, lower D-dimer fragments, and lower von Willebrand factor levels. Normal endothelial function and reduction of IMT was observed only in patients undergoing KP transplantation.

Entities:  

Mesh:

Year:  2001        PMID: 11246868     DOI: 10.2337/diabetes.50.3.496

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  15 in total

Review 1.  Islet versus pancreas transplantation in type 1 diabetes: competitive or complementary?

Authors:  Barbara Ludwig; Stefan Ludwig; Anja Steffen; Hans-Detlev Saeger; Stefan R Bornstein
Journal:  Curr Diab Rep       Date:  2010-12       Impact factor: 4.810

Review 2.  The effect of whole organ pancreas transplantation and PIT on diabetic complications.

Authors:  Timothy C Lee; Neal R Barshes; Erin E Agee; Christine A O'Mahoney; F Charles Brunicardi; John A Goss
Journal:  Curr Diab Rep       Date:  2006-08       Impact factor: 4.810

3.  Circulating IGF-I and IGFBP3 Levels Control Human Colonic Stem Cell Function and Are Disrupted in Diabetic Enteropathy.

Authors:  Francesca D'Addio; Stefano La Rosa; Anna Maestroni; Peter Jung; Elena Orsenigo; Moufida Ben Nasr; Sara Tezza; Roberto Bassi; Giovanna Finzi; Alessandro Marando; Andrea Vergani; Roberto Frego; Luca Albarello; Annapaola Andolfo; Roberta Manuguerra; Edi Viale; Carlo Staudacher; Domenico Corradi; Eduard Batlle; David Breault; Antonio Secchi; Franco Folli; Paolo Fiorina
Journal:  Cell Stem Cell       Date:  2015-10-01       Impact factor: 24.633

Review 4.  Immunological applications of stem cells in type 1 diabetes.

Authors:  Paolo Fiorina; Julio Voltarelli; Nicholas Zavazava
Journal:  Endocr Rev       Date:  2011-08-23       Impact factor: 19.871

Review 5.  Transplantation of the pancreas.

Authors:  Ugo Boggi; Fabio Vistoli; Francesca Maria Egidi; Piero Marchetti; Nelide De Lio; Vittorio Perrone; Fabio Caniglia; Stefano Signori; Massimiliano Barsotti; Matteo Bernini; Margherita Occhipinti; Daniele Focosi; Gabriella Amorese
Journal:  Curr Diab Rep       Date:  2012-10       Impact factor: 4.810

Review 6.  Pancreas and kidney transplantation.

Authors:  Jennifer Larsen; James Lane; Lynn Mack-Shipman
Journal:  Curr Diab Rep       Date:  2002-08       Impact factor: 4.810

Review 7.  Vascular reactivity in diabetes mellitus.

Authors:  Ajay Chaudhuri
Journal:  Curr Diab Rep       Date:  2002-08       Impact factor: 4.810

8.  Proteomics reveals novel oxidative and glycolytic mechanisms in type 1 diabetic patients' skin which are normalized by kidney-pancreas transplantation.

Authors:  Franco Folli; Valeria Guzzi; Lucia Perego; Dawn K Coletta; Giovanna Finzi; Claudia Placidi; Stefano La Rosa; Carlo Capella; Carlo Socci; Davide Lauro; Devjit Tripathy; Christopher Jenkinson; Rita Paroni; Elena Orsenigo; Giuliana Cighetti; Luisa Gregorini; Carlo Staudacher; Antonio Secchi; Angela Bachi; Michael Brownlee; Paolo Fiorina
Journal:  PLoS One       Date:  2010-03-29       Impact factor: 3.240

9.  Twelve-month pancreas graft function significantly influences survival following simultaneous pancreas-kidney transplantation.

Authors:  Andrew S Weiss; Gerard Smits; Alexander C Wiseman
Journal:  Clin J Am Soc Nephrol       Date:  2009-04-30       Impact factor: 8.237

Review 10.  Risks and side effects of islet transplantation.

Authors:  Edmond A Ryan; Breay W Paty; Peter A Senior; A M James Shapiro
Journal:  Curr Diab Rep       Date:  2004-08       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.